• Explore /
  • Videos & Slides
  • / First-in-class, first-in-human phase I trial of KPT-330, a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors.

First-in-class, first-in-human phase I trial of KPT-330, a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors.

Abstract Video & Slides

Presenter

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Videos & Slides Details

Meeting

2013 ASCO Annual Meeting

Session Type

Oral Abstract Session

Session Title

Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics

Track

Developmental Therapeutics

Sub Track

Cytotoxic and Other Novel Agents

Clinical Trial Registration Number

NCT01607905

Citation

J Clin Oncol 31, 2013 (suppl; abstr 2505)

DOI

10.1200/jco.2013.31.15_suppl.2505

Abstract #

2505

Abstract Disclosures

Similar Videos & Slides

Speaker: Nehal J. Lakhani, MD, PhD

Videos & Slides

2024 ASCO Annual Meeting

Daring to Cure: No One Left Behind

Daring to Cure: No One Left Behind

Speaker: Suthee Rapisuwon, MD

Speaker: Jacob Stephen Thomas, MD

Speaker: Shukui Qin, MD